Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: A retrospective study

Medical Science Monitor

Volumn 9, Issue 6, 2003, Pages

  Drzewoski, Józef ^a   Czupryniak, Leszek ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Barlicki University Hospital ^*  (Poland)

Author keywords

Body weight; Efficacy; Insulin requirement; Metformin; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BASAL METABOLIC RATE; BODY WEIGHT; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037830328     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gerich JE: Oral hypoglycemic agents. N Engl J Med, 1989; 321: 1231-45
2. Davidson MB, Peters AL: An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med, 1997; 102: 99-110
3. Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-II Study. Am J Med, 1997; 103: 483-90
4. Garber AJ, Duncan TG, Goodmann AM et al: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med, 1997; 102: 491-7
5. United Kingdom Prospective Diabetes Group: Effect of intensive blood glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet, 1998; 352: 854-65
6. Johansen K: Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care, 1999; 22: 33-7
7. Dornan TL, Heller SR, Peck GM, Tattersall RB: Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care, 1991; 14: 342-4
8. DeFronzo RA, Goodman AM: The Multicenter Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med, 1995; 333: 541-9
9. Hermann LS, Schersten B, Melander A: Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulfonylurea, alone and in primary combination. Diabet Med, 1994; 11: 953-60
10. Carlsen SM, Grill V, Foiling I: Evidence for dissociation of insulin-and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. Diabetes Res Clin Pract, 1998; 39: 47-54
11. Giugliano D, Quatraro A, Consoli G et al: Metformin for obese, insulin-treated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol, 1993; 44: 107-12
12. Holstein A, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin are largely disregarded. Diabet Med, 1999; 16: 692-6
13. Rosenbloom AL, Joe JR, Young RS, Winter WE: Emerging epidemic of type 2 diabetes in youth. Diabetes Care, 1999; 22: 345-54